Last week, just in time for the sexiest holiday of the year, the film Orgasm Inc. opened. Despite its racy title and advertising, though, the film's message is a bit more sobering. It examines the commercial medicalization of female sexuality, specifically the race between pharmaceutical companies to find and patent a female form of Viagra, be it a topical cream, pill or hormonal patch. Filmmaker Liz Canner was originally hired to create explicit content for the drug company Vivus for their clinical trials, which lead her to her own documentation of how drug companies develop and talk about their drugs for improving female sexual functionality. Throughout the film, she illuminates how drug makers are neck in neck to get FDA approval to cure the disease known as "Female Sexual Dysfunction" (FSD), an ailment that some physicians and sexuality experts claim was fabricated by the drug companies themselves in order to open up a large potential market: namely, women experiencing concerns regarding their own sexual normalcy and sexual well being.For instance, the film follows one woman who undergoes a dangerous and potentially paralyzing procedure as a case study subject for a new device called the "Orgasmatron" (no mention of Woody Allen's Sleeper here, though). During her interview, she stresses how she simply wants to feel "normal," which she defines as being able to achieve orgasm through vaginal intercourse (most women require some form of clitoral stimulation to achieve orgasm - to find out more about simultaneous orgasms with your partner, check out this article from our website). The feelings expressed by this interviewee are just a part of the important and enlightening messages threaded through the film about the ways in which American women are misinformed, misdirected and manipulated into believing their sexual experiences are mysterious, unnatural or diseased. To find out more about the culture from which FSD was created, check out Dallas' article on the subject from the Babeland Blog. Orgasm Inc. is currently in limited release and expected to be available for purchase in April.